Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137693 | Leukemia Research | 2010 | 7 Pages |
Abstract
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN™), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of ≤30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Walter Fiedler, Rolf Mesters, Michael Heuser, Gerhard Ehninger, Wolfgang E. Berdel, Ute Zirrgiebel, Jane D. Robertson, Tom A. Puchalski, Barbara Collins, Juliane M. Jürgensmeier, Hubert Serve,